DOCSLIB.ORG

(19) United States (12) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(19) United States (12) Patent Application Publication (10) Pub US 20060045850A1 (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2006/0045850 A1 Namburi et al. (43) Pub. Date: Mar. 2, 2006 (54) NASAL DELIVERY OF CYCLODEXTRIN Publication Classi?cation COMPLEXES OF ANTI-INFLAMMATORY STEROIDS (51) Int. Cl. A61K 31/724 (2006.01) A61K 9/14 (2006.01) A61L 9/04 (2006.01) (75) Inventors: Ranga R. Namburi, Plainsboro, NJ (52) Us. 01. ............................................... ..424/46; 514/58 (US); Sucharitha Jagini, Edison, NJ (US); Burgise F. Palkhiwala, East (57) ABSTRACT Windsor, NJ (US) Aqueous, anti-in?ammatory steroid compositions in solu tion form suitable for nasal administration and having a reduced stinging sensation are provided as Well as a method Correspondence Address: for treating in?ammation of the nasal mucosa by intranasal Richard S. Roberts administration of anti-in?ammatory steroid compositions. These solution compositions may result in enhanced nasal PO. Box 484 bio-availability. The anti-in?ammatory steroid composition Princeton, NJ 08542-0484 (US) suitable for intranasal administration includes an anti-in ?ammatory steroid in an amount of from about 0.0001% to about 2.0% (W/v); a cyclodextrin in an amount of from about (73) Assignee: QPharma, LLC 0.1% to about 20% (W/v); an alcohol co-solvent in an amount of from about 0.2% to about 35% (W/v); a crystal lization inhibitor Where required, an effective amount of an (21) Appl. No.: 10/930,986 antimicrobial preservative; an effective amount of an anti oxidant; an effective amount of a chelating agent; Water; and a pH adjusting agent sufficient to adjust the pH of the (22) Filed: Aug. 30, 2004 composition to from about 4 to about 7. US 2006/0045850 A1 Mar. 2, 2006 NASAL DELIVERY OF CYCLODEXTRIN lation for use in female contraception and the composition is COMPLEXES OF ANTI-INFLAMMATORY comprised of a GnRH compound and an estrogenic com STEROIDS pound in the form of Water soluble complex With a Water soluble cyclodextrin. The method used to combine cyclo BACKGROUND OF THE INVENTION dextrins and hormones in these patents is different from this invention. US. Pat. No. 5,089,482 combines cyclodextrin [0001] 1. Field of the Invention With the hormones through using a solvent and removing the [0002] The present invention pertains to aqueous solution, solvent through evaporation process and the complex that is anti-in?ammatory steroid compositions suitable for nasal formed in this process is combined With other formulation administration. The invention also pertains to a method for excipients. Thus there is a need for formation of a clear treating in?ammation of the nasal mucosa by intranasal solution formulation of the steroids using simple and indus administration of anti-in?ammatory steroid compositions. trially feasible appropriate methods. The compositions of More particularly, the invention pertains to stable anti the present invention are stable, preservable, and are suitable in?ammatory steroid compositions for intranasal adminis for nasal administration of anti-in?ammatory steroids and tration having a reduced stinging sensation. The invention have a reduced stinging tendency. In this invention a mini formulations in solution form may result in enhanced bio mum amount of co-solvent (adjuvant) is used to dissolve the availability from the nose. active steroid With application of heat and it is then com bined With aqueous phase containing cyclodextrin. The [0003] 2. Description of the Related Art invention also proves that cyclodextrin forms a complex [0004] Anti-in?ammatory steroid compositions suitable With the active and remains in solution in spite of the fact for nasal administration are knoWn in the art. Typically these that loW percentage of cosolvent is used in the formulation. include a cortical steroid such as ?unisolide, beclometha The invention formulations of beclomethasone dipropionate sone dipropionate, budenoside, mometasone furoate or ?u and ?uticasone propionate teach the addition of a crystalli ticasone propionate. Anti-in?ammatory steroids are di?icult Zation inhibitor, such as hydroxy propyl methyl cellulose, in to formulate in aqueous solutions due to their poor solubility the formulation to prevent precipitation upon storage in vieW in Water. Acceptable formulations must be able to dissolve of their extremely loW solubility in Water and also their an active compound Without precipitation or suspend the molecular siZe. The solubility and stability of beclometha active Without agglomeration or particle siZe increase upon sone and ?uticasone is increased in presence of crystalliZa storage or undue oxidation of the components, i.e. they must tion inhibitor such as hydroxyl propyl methyl cellulose. be stable. Suitable formulations must also avoid discomfort to the user. Aqueous compositions of anti-in?ammatory SUMMARY OF THE INVENTION steroids such as ?unisolide suitable for nasal administration [0006] The invention provides an anti-in?ammatory ste are commercially available, for example under the trade roid composition suitable for intranasal administration marks Nasalide® and Nasarel®. HoWever, currently avail Which comprises: able compositions, While safe and effective, are knoWn to cause stinging upon administration in some cases. Such a [0007] an anti-in?ammatory steroid in an amount of side effect is particularly undesirable When treating nasal from about 0.0001% to about 2.0% (W/v); in?ammation. Adjuvants such as propylene glycol in higher concentration (more than 10 percent), Polysorbate 80 or [0008] a cyclodextrin in an amount of from about 0.1% to about 20% (W/v); TWeen 80 suitable for use as solubiliZers, hoWever, are often unsuitable for the nasal mucosa and/or have an insu?icient [0009] an alcohol co-solvent in an amount of from solubility. A chronic therapy With such a composition is about 0.2% to about 35% (W/v); undesirable. [0010] an effective amount of an antimicrobial preser [0005] Nasonex® (Mometasone Furoate), Beconase AQ® vative; (Beclomethasone Dipropionate), Nasacort AQ®A (Triamci nolone Acetonide), Rhinocort® Aqua (Budenoside) and [0011] 1an effective amount of an antioxidant; Flonase® (Fluticasone Propionate) are marketed formula [0012] 1an effective amount of a chelating agent; tions With actives suspended. Absolute bio-availability of these suspension formulations is loW and for example the [0013] Water; and absolute bio-availability of Fluticasone from the suspension formulation When administered nasally is less than 2.0 [0014] a pH adjusting agent su?icient to adjust the pH percent and it has no absorption When administered orally. of the composition to from about 4 to about 7. Hence, there is a clear need for development of clear [0015] The composition may also contain a crystalliZation solution formulations of the steroids. US. Pat. No. 6,241, inhibitor in an amount of from about 0.01% to 10% W/V. 969 provides aqueous compositions containing corticoster oids for nasal and pulmonary delivery Which comprises at [0016] The invention also provides a method of treating least 50% by Weight of an ethoxylated derivative of vitamin in?ammation of the nasal mucosa, Which method comprises E. US. Pat. Nos. 4,782,047 and 4,983,595 shoW an aqueous intranasally administering to a subject in need thereof an steroid formulation for nasal administration, hoWever, no anti-in?ammatory steroid composition comprising: cyclodextrins are taught. US. Pat. Nos. 5,089,482, 5,955, [0017] an anti-in?ammatory steroid in an amount of 454 and WO 00/21503 shoW aqueous formulations of hor from about 0.0001% to about 2.0% (W/v); mones for nasal administration using cyclodextrins, hoW ever, no corticosteroids are shoWn. US. patent application [0018] a cyclodextrin in an amount of from about 0.1% 2004022739 also teaches preparation of nasal spray formu to about 20% (W/v); US 2006/0045850 A1 Mar. 2, 2006 [0019] an alcohol co-solvent in an amount of from most useful pharmaceutical complexing agent due to its about .2% to about 35% (W/v); cavity siZe, availability, loW cost and other properties. Cyclodextrin derivatives of current pharmaceutical interest [0020] an effective amount of an antimicrobial preser include the hydroxypropyl derivatives of ot-, [3- and y-cy vat1ve; clodextrin, sulfoalkylether cyclodextrins such as sulfobu [0021] an effective amount of an antioxidant; tylether [3-cyclodextrin, alkylated cyclodextrins such as the randomly methylated [3-cyclodextrin, and various branched [0022] an effective amount of a chelating agent; cyclodextrins such as glucosyl- and maltosyl [3-cyclodextrin. [0023] Water; and [0029] In aqueous solutions, cyclodextrins form inclusion [0024] a pH adjusting agent suf?cient to adjust the pH complexes With many drugs through a process in Which the of the composition to from about 4 to about 7. Water molecules located in the central cavity are replaced by either the Whole drug molecule, or more frequently, by some [0025] The composition may also contain a crystallization lipophilic portion of the drug structure. Once included in the inhibitor in an amount of from about 0.01% to 10% W/V. cyclodextrin cavity, the drug molecules may be dissociated [0026] Commercially available metered dose pumps and through complex dilution, by replacement of the included bottles are used for ?lling of the invention formulations. drug by some other suitable molecule or, the drug may be transferred to the matrix for Which it has the highest affinity. DETAILED DESCRIPTION OF THE Importantly, since no covalent bonds are formed or broken INVENTION during the drug-cyclodextrin complex formation, the com plexes are in dynamic equilibrium With free drug and [0027] The composition of the invention includes an anti cyclodextrin molecules. In solution, the complexes are usu in?ammatory steroid, such as a corticosteroid. The corticos ally prepared by addition of an excess amount of the drug to teroids that are useful in the present invention generally an aqueous cyclodextrin solution. The suspension formed is include any steroid produced by the adrenocortex, including and then ?ltered or centrifuged to form a clear drug glucocorticoids and mineralocorticoids, and synthetic ana cyclodextrin complex solution.
Load more

Recommended publications
  • Do Intra-Articular Steroid Injections Affect Glycemic Control in Patients
    Evidence-based answers from the Family Physicians Inquiries Network Erin Kallock, MD; Do intra-articular steroid Jon O. Neher, MD Valley Family Medicine Residency, Renton, Wash. injections aff ect glycemic control Leilani St. Anna, MLIS, AHIP University of Washington in patients with diabetes? Health Services Library, Seattle EVIDENCE-BASED ANSWER yes, but the clinical importance mendation [SOR]: B, small cohort studies). A is minimal. A single intra-articular Intra-articular steroid injections into the steroid injection into the knee produces shoulder may briefl y raise postprandial (but acute hyperglycemia for 2 or 3 days in pa- not mean) glucose levels with larger and re- tients with diabetes who otherwise have peated doses (SOR: C, extrapolated from het- good glucose control (strength of recom- erogenous and mixed cohort studies). A single steroid injection into the knee joint Evidence summary 1 week; investigators measured fructosamine causes acute Two prospective cohort studies evaluated the levels (a measure of intermediate-term hyperglycemia eff ect on glycemic control of a single gluco- glucose control) at baseline and again for 2 or 3 days corticoid injection into the knee of patients 2 weeks after injection. in patients with with controlled type 2 diabetes (glycosylated Th e injection produced hyperglycemia in diabetes who hemoglobin A1c Ͻ7.0%). Th e fi rst enrolled all participants, with peak blood glucose lev- otherwise have 9 patients with symptomatic osteoarthritis of els ranging from 251 to 430 mg/dL and time to good glucose the knee unresponsive to 3 months of nonste- peak glucose usually less than 6 hours. Fruc- control.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Immediate Hypersensitivity Reactions Caused by Drug Excipients: a Literature Review Caballero ML, Quirce S
    REVIEWS Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review Caballero ML, Quirce S Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain J Investig Allergol Clin Immunol 2020; Vol. 30(2): 86-100 doi: 10.18176/jiaci.0476 Abstract The European Medicines Agency defines excipients as the constituents of a pharmaceutical form apart from the active substance. Immediate hypersensitivity reactions (IHRs) caused by excipients contained in the formulation of medications have been described. However, there are no data on the prevalence of IHRs due to drug excipients. Clinical manifestations of allergy to excipients can range from skin disorders to life-threatening systemic reactions. The aim of this study was to review the literature on allergy to pharmaceutical excipients and to record the IHRs described with various types of medications, specifically reactions due to the excipients contained in their formulations. The cases reported were sorted alphabetically by type of medication and excipient in order to obtain a list of the excipients most frequently involved for each type of medication. Key words: Allergy. Drug immediate hypersensitivity reaction. Excipient. Pharmaceutical excipients. Resumen La Agencia Europea de Medicamentos define los excipientes como los componentes de una forma farmacéutica diferenciados del principio activo. Se han descrito reacciones de hipersensibilidad inmediata causadas por los excipientes contenidos en la formulación de medicamentos. Sin embargo, no hay datos sobre la prevalencia de dichas reacciones. Las manifestaciones clínicas de la alergia a los excipientes pueden ir desde trastornos de la piel hasta reacciones sistémicas que ponen en peligro la vida. El objetivo de este estudio fue realizar una revisión de la literatura sobre la alergia a los excipientes farmacéuticos y recopilar las reacciones inmediatas descritas con diferentes tipos de medicamento, debido solo a excipientes contenidos en sus formulaciones.
    [Show full text]
  • Ep 0173478 A1
    Patentamt JEuropaischesJ European Patent Office @ Publication number: 0173 478 ^ ^ Office europeen des brevets EUROPEAN PATENT APPLICATION Application number: 85305552.3 © 'nt. CI ": A 61 K 35/78, A 61 K 31 /57 Dateof filing: 05.08.85 (A61K35/78, 31 :57),(A61K31/57, 31 :23, 31 :20) @ Priority: 15.08.84 GB 8420771 @ Applicant: EFAMOL LIMITED, Efamol House Woodbridge Meadows, Guildford Surrey GU1 1BA (GB) @ Date of publication of application: 05.03.86 @ Bulletin 86/10 efamol House woodbridge meadows, Guildford Surrey GU1 1BA (GB) @ Representative : Caro, William Egerton et al, J. MILLER & @ Designated Contracting States: AT BE CH DE FR GB IT CO. Lincoln House 296-302 High Holborn, London LILUNLSE WC1V7JH(GB) @ Treatment of skin disorders. A topical composition for skin treatment contains an anti- inflammatory glucocorticoid in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent poly- unsaturated fatty acid, as such or in the form of a physio- logically acceptable derivative convertible in the body thereto. FIELD OF INVENTION The invention relates to compositions of y-linolenic acid and related materials with anti-inflammatory glucocorticoids and to the treatment of inflammatory skin disorders with them. BACKGROUND AND EXPLANATION OF INVENTION Much interest has been shown in recent years in essential fatty acid metabolism, especially in its relation to prosta- glandin (PG) metabolism and in particular to the balance of 1-series and 2-series PGs in the body. The main dietary essential fatty acid (EFA) utilised in the fully healthy human body is linoleic acid, but the Δ6- desaturase that converts it to the next acid in the n-6 series, namely y-linoleic acid (GLA) is at a low level of activity in many conditions.
    [Show full text]
  • Contact Dermatitis to Medications and Skin Products
    Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
    [Show full text]
  • Decadron® (Dexamethasone Tablets, Usp)
    NDA 11-664/S-062 Page 3 TABLETS DECADRON® (DEXAMETHASONE TABLETS, USP) DESCRIPTION DECADRON* (dexamethasone tablets, USP) tablets, for oral administration, are supplied in two potencies, 0.5 mg and 0.75 mg. Inactive ingredients are calcium phosphate, lactose, magnesium stearate, and starch. Tablets DECADRON 0.5 mg also contain D&C Yellow 10 and FD&C Yellow 6. Tablets DECADRON 0.75 mg also contain FD&C Blue 1. The molecular weight for dexamethasone is 392.47. It is designated chemically as 9-fluoro-11β,17,21- trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The empirical formula is C22H29FO5 and the structural formula is: Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water. CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Glucocorticoids cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have sodium-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs including dexamethasone are primarily used for their anti-inflammatory effects in disorders of many organ systems. At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone. INDICATIONS AND USAGE Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al
    US007544192B2 (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton et al. (45) Date of Patent: Jun. 9, 2009 (54) SINUS DELIVERY OF SUSTAINED RELEASE 5,443,498 A 8, 1995 Fontaine THERAPEUTICS 5,512,055 A 4/1996 Domb et al. 5,664,567 A 9, 1997 Linder (75) Inventors: Donald J. Eaton, Woodside, CA (US); 5,693,065. A 12/1997 Rains, III Mary L. Moran, Woodside, CA (US); 5,792,100 A 8/1998 Shantha Rodney Brenneman, San Juan Capistrano, CA (US) (73) Assignee: Sinexus, Inc., Palo Alto, CA (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 992 days. WO WOO1/02024 1, 2001 (21) Appl. No.: 10/800,162 (22) Filed: Mar 12, 2004 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2005/OO437O6A1 Feb. 24, 2005 Hosemann, W. et al. (Mar. 2003, e-pub. Oct. 10, 2002). “Innovative s Frontal Sinus Stent Acting as a Local Drug-Releasing System.' Eur: Related U.S. Application Data Arch. Otorhinolarynolo. 260:131-134. (60) Provisional application No. 60/454,918, filed on Mar. (Continued) 14, 2003. Primary Examiner Kevin C Sirmons (51) Int. Cl Assistant Examiner Catherine NWitczak A. iM sI/00 (2006.01) (74) Attorney, Agent, or Firm Morrison & Foerster LLP (52) U.S. Cl. ........................ 604/506; 604/510; 604/514 (57) ABSTRACT (58) Field of Classification Search .............. 604/93.01, 604/891.1. 890.1, 57, 59-64, 510, 514,506; S lication file f 606/196 The invention provides biodegradable implants for treating ee application file for complete search history.
    [Show full text]
  • Improved Penetrating Topical Pharmaceutical Compositions Containing Corticosteroids
    Europaisches Patentamt ® European Patent Office © Publication number: 0 129 283 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION © Application number: 84200821.1 ©Int CI.3: A 61 K 31/57 A 61 K 47/00, A 61 K 9/06 © Date of filing: 12.06.84 © Priority: 21.06.83 US 506274 © Applicant: THE PROCTER & GAMBLE COMPANY 01.02.84 US 576065 301 East Sixth Street Cincinnati Ohio 45201 (US) © Date of publication of application: © Inventor: Cooper, Eugene Rex 27.12.84 Bulletin 84/52 2425 Ambassador Drive Cincinnati, OH 45231 (US) © Designated Contracting States: BE CH DE FR GB IT Li NL SE © Inventor: Loomans, Maurice Edward 5231 Jessup Road Cincinnati, OH 45239IUS) © Inventor: Fawzi, Mahdi Bakir 11 Timberline Drive Flanders New Jersey 07836(US) © Representative: Suslic, Lydia et al, Procter & Gamble European Technical Center Temselaan 100 B-1820 Strombeek-Bever(BE) © Improved penetrating topical pharmaceutical compositions containing corticosteroids. Topical pharmaceutical compositions containing a cor- ticosteroid component and a penetration-enhancing vehicle are disclosed. The vehicle comprises a binary combination of a C3-C4 diol and a "cell-envelope disordering compound". The vehicle provides marked transepidermal and percutaneous delivery of corticosteroids. A method of treating certain rheumatic and inflammatory conditions, systemically or loc- ally, is also disclosed. TECHNICAL FIELD The present invention relates to topical compositions effective in delivering high levels of certain pharmaceutically-active cor- ticosteroid agents through the integument. Because of the ease of access, dynamics of application, large surface area, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the treatment, the delivery of pharmaceutically-active agents through the skin has long been a promising concept.
    [Show full text]
  • Glucocorticoids in the Treatment of Glomerular Diseases Pitfalls and Pearls
    Glucocorticoids in the Treatment of Glomerular Diseases Pitfalls and Pearls Claudio Ponticelli1 and Francesco Locatelli2 Abstract 1Division of Glucocorticoids exert anti-inflammatoryand immunosuppressiveactivities by genomic and nongenomic effects. The Nephrology, Ospedale classic genomic effects are mediated by cytosolic glucocorticoid receptors that can upregulate the expression of anti- Maggiore, Milano, Italy; and 2Division of inflammatory proteins in the nucleus (transactivation) or repress the translocation of proinflammatory transcription Nephrology, Ospedale factors from the cytosol into the nucleus (transrepression). The nongenomic effects are probably mediated by Alessandro Manzoni, membrane glucocorticoid receptors. Glucocorticoid receptors are expressed also in podocytes and experimental Lecco, Italy data suggestthat glucocorticoidsmay protect from podocyteinjury.Glucocorticoids havealowtherapeutic index and may exert a number of time-dependent and dose-dependent side effects. Measures to prevent or attenuate side effects Correspondence: include single-morning administration of short-acting glucocorticoids, dietetic counseling, increasing physical Dr. Claudio Ponticelli, Past Director activity, frequent monitoring, and adapting the doses to the clinical conditions of the patient. Synthetic Nephrology, Ospedale glucocorticoids, either given alone or in combination with other immunosuppressive drugs, are still the cornerstone Maggiore, Milano, therapy in multiple glomerular disorders. However, glucocorticoids are of little benefit in C3 glomerulopathy Italy. Email: ponticelli. and may be potentially deleterious in patients with maladaptive focal glomerulosclerosis. Their efficacy depends [email protected] not only on the type and severity of glomerular disease, but also on the timeliness of administration, the dosage, and the duration of treatment. Whereas an excessive use of glucocorticoids can be responsible for severe toxicity, too low a dosage and too short duration of glucocorticoid treatment can result in false steroid resistance.
    [Show full text]
  • Steroid Use in Clinical Practice
    Steroid Use In Clinical Practice DR. TIN WIN AUNG Consultant Endocrinologist Department of Diabetes & Endocrinology North Okkalapa General & Teaching Hospital Outlines ◼ Overview of Steroids → What are steroids? →Steroidogenesis, Regulation, Physiological & Adverse Effects ◼ Steroids use in Clinical practice → Classification → Topical Steroids → Inhaled Corticosteroids → Systemic Corticosteroids → Prevention & Treatment of Complications of using CS What are steroids? ◼ Steroids (short for corticosteroids) are synthetic drugs that closely resemble cortisol, a hormone that your adrenal glands produce naturally. ◼ Corticosteroids are different from the male hormone-related steroid compounds that some athletes use. Corticosteroids ◼ Corticosteroids divided into: –Glucocorticoids –Mineralocorticoids Endogenous Steroidogenesis Regulation of Cortisol Secretion ◼ Three major mechanisms control ACTH release and the Cortisol secretion (1) Negative feedback mechanism →ACTH from anterior pituitary (2) Diurnal variation →Levels are the highest in the morning on waking and the lowest in the middle of evening. (3) Stress- physical (trauma, surgery, exercise) - psychological (pain, anxiety, apprehension) - physiological (nausea, fever and hypoglycemia) The Role of Cortisol in Regulation of HPA Axis 20 mg/day Plasma Cortisol -140- 700 nmol/l (Ref: range) Glucocorticoids Physiological Effects Carbohydrate metabolism ↑gluconeogenesis and conserve glucose for use during stress or starvation. Protein metabolism catabolic effect → negative nitrogen balance
    [Show full text]
  • Serious Neurological Events Complicating Epidural Injections Of
    RMD Open: first published as 10.1136/rmdopen-2016-000320 on 22 September 2016. Downloaded from Editorial Serious neurological events complicating epidural injections of glucocorticoid suspensions: evidence for a direct effect of some particulate steroids on red blood cells Jean-Denis Laredo,1 Elisabeth Laemmel,2 Eric Vicaut2 To cite: Laredo J-D, The Food and Drug Administration (FDA) into the vertebral artery has also been Laemmel E, Vicaut E. Serious has not approved any injectable glucocortic- demonstrated in an animal study.7 Occlusion neurological events complicating epidural oid product for epidural administration, but of distal intramedullary arteries by steroid injections of glucocorticoid epidural injection of glucocorticoids is com- particles via an unexpected intra-arterial suspensions: evidence for a monly used to manage radicular neck and injection has been incriminated as the mech- direct effect of some back pain.1 Severe and sometimes fatal anism leading to cord infarction in severe particulate steroids on red neurological events have occurred immedi- neurological deficit occurring after foraminal blood cells. RMD Open 8 2016;2:e000320. doi:10.1136/ ately after epidural injection of glucocorti- steroid injections at the cervical spine. It has rmdopen-2016-000320 coids. Indeed, 90 events were reported to the been suggested that the tendency of steroid FDA Adverse Event Reporting System particles to coalesce and the size of their 2 fi ▸ Prepublication history and (FAERS) between 1997 and 2014. nal aggregates, which differ among the dif- additional material for this In the December 10, 2015 issue of the New ferent types of particulate steroids, may influ- 2 paper is available online.
    [Show full text]